Evidence map›Paper›PMID 40573322›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

In Vivo PK-PD and Drug-Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia.

Guanqin Jin, Kewei Zheng, Shihuang Liu, Huan Yi, Wei Wei, Congjian Xu, Xiaoqiang Xiang, Yu Kang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guanqin JinClinical Research Center, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200433, China.ORCID 0000-0001-8104-5718
Kewei ZhengShanghai Key Lab of Female Reproductive Endocrine Related Diseases, Shanghai 200433, China.
Shihuang LiuDepartment of Gynecologic Oncology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350001, China.
Huan YiDepartment of Gynecologic Oncology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350001, China.
Wei WeiDepartment of Translational Medicine, Shanghai Jiatan Pharmatech Co., Ltd., Shanghai 201203, China.
Congjian XuShanghai Key Lab of Female Reproductive Endocrine Related Diseases, Shanghai 200433, China.
Xiaoqiang XiangDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.ORCID 0000-0002-8683-2603
Yu KangClinical Research Center, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200433, China.

Funding

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases (Obstetrics and Gynecology Hospital, Fudan University) 20DZ2271300the National Key Research and Development Program of China 2022YFC2705004
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

dorzagliatinLC-MS/MS analysisP-gp-mediated drug–drug interactionPI3Kα inhibitorsPK/PD models

Identifiers

PMID40573322
PMCPMC12196043

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.